Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

Neoantigens derived from tumor-specific genetic mutations might be suitable targets for cancer immunotherapy because of their high immunogenicity. In the current study, we evaluated the immunogenicity of 10 driver mutations that are frequently expressed in various cancers using peripheral blood mono...

Full description

Bibliographic Details
Main Authors: Susumu Iiizumi, Junya Ohtake, Naoko Murakami, Taku Kouro, Mamoru Kawahara, Fumiko Isoda, Hiroshi Hamana, Hiroyuki Kishi, Norihiro Nakamura, Tetsuro Sasada
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
neoantigen
driver mutation
MHC class II epitope
Online Access:https://www.mdpi.com/2072-6694/11/2/266

Internet

https://www.mdpi.com/2072-6694/11/2/266

Similar Items